Literature DB >> 22258236

A novel approach for the rapid mutagenesis and directed evolution of the structural genes of west nile virus.

Tsai-Yu Lin1, Kimberly A Dowd, Carolyn J Manhart, Steevenson Nelson, Stephen S Whitehead, Theodore C Pierson.   

Abstract

Molecular clone technology has proven to be a powerful tool for investigating the life cycle of flaviviruses, their interactions with the host, and vaccine development. Despite the demonstrated utility of existing molecular clone strategies, the feasibility of employing these existing approaches in large-scale mutagenesis studies is limited by the technical challenges of manipulating relatively large molecular clone plasmids that can be quite unstable when propagated in bacteria. We have developed a novel strategy that provides an extremely rapid approach for the introduction of mutations into the structural genes of West Nile virus (WNV). The backbone of this technology is a truncated form of the genome into which DNA fragments harboring the structural genes are ligated and transfected directly into mammalian cells, bypassing entirely the requirement for cloning in bacteria. The transfection of cells with this system results in the rapid release of WNV that achieves a high titer (∼10(7) infectious units/ml in 48 h). The suitability of this approach for large-scale mutagenesis efforts was established in two ways. First, we constructed and characterized a library of variants encoding single defined amino acid substitutions at the 92 residues of the "pr" portion of the precursor-to-membrane (prM) protein. Analysis of a subset of these variants identified a mutation that conferred resistance to neutralization by an envelope protein-specific antibody. Second, we employed this approach to accelerate the identification of mutations that allow escape from neutralizing antibodies. Populations of WNV encoding random changes in the E protein were produced in the presence of a potent monoclonal antibody, E16. Viruses resistant to neutralization were identified in a single passage. Together, we have developed a simple and rapid approach to produce infectious WNV that accelerates the process of manipulating the genome to study the structure and function of the structural genes of this important human pathogen.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22258236      PMCID: PMC3302547          DOI: 10.1128/JVI.06435-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  79 in total

1.  Essential role of cyclization sequences in flavivirus RNA replication.

Authors:  A A Khromykh; H Meka; K J Guyatt; E G Westaway
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

2.  Structure of dengue virus: implications for flavivirus organization, maturation, and fusion.

Authors:  Richard J Kuhn; Wei Zhang; Michael G Rossmann; Sergei V Pletnev; Jeroen Corver; Edith Lenches; Christopher T Jones; Suchetana Mukhopadhyay; Paul R Chipman; Ellen G Strauss; Timothy S Baker; James H Strauss
Journal:  Cell       Date:  2002-03-08       Impact factor: 41.582

3.  Proper processing of dengue virus nonstructural glycoprotein NS1 requires the N-terminal hydrophobic signal sequence and the downstream nonstructural protein NS2a.

Authors:  B Falgout; R Chanock; C J Lai
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

4.  Fusion activity of flaviviruses: comparison of mature and immature (prM-containing) tick-borne encephalitis virions.

Authors:  F Guirakhoo; F X Heinz; C W Mandl; H Holzmann; C Kunz
Journal:  J Gen Virol       Date:  1991-06       Impact factor: 3.891

5.  Relative rates of homologous and nonhomologous recombination in transfected DNA.

Authors:  D B Roth; J H Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

6.  Immune response to synthetic peptides of dengue prM protein.

Authors:  Susana Vázquez; María Guadalupe Guzmán; Gerardo Guillen; Glay Chinea; Ana Beatriz Pérez; Maritza Pupo; Rosmary Rodriguez; Osvaldo Reyes; Hilda Elisa Garay; Iselys Delgado; Gissel García; Mayling Alvarez
Journal:  Vaccine       Date:  2002-03-15       Impact factor: 3.641

7.  Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation.

Authors:  C M Rice; A Grakoui; R Galler; T J Chambers
Journal:  New Biol       Date:  1989-12

8.  Site-directed mutagenesis by overlap extension using the polymerase chain reaction.

Authors:  S N Ho; H D Hunt; R M Horton; J K Pullen; L R Pease
Journal:  Gene       Date:  1989-04-15       Impact factor: 3.688

9.  Antigenic variation in three distinct determinants of an influenza type A haemagglutinin molecule.

Authors:  J W Yewdell; R G Webster; W U Gerhard
Journal:  Nature       Date:  1979-05-17       Impact factor: 49.962

Review 10.  Antigenic structure of flavivirus proteins.

Authors:  John T Roehrig
Journal:  Adv Virus Res       Date:  2003       Impact factor: 9.937

View more
  17 in total

Review 1.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

2.  A novel bacterium-free method for generation of flavivirus infectious DNA by circular polymerase extension reaction allows accurate recapitulation of viral heterogeneity.

Authors:  Judith Edmonds; Erinke van Grinsven; Natalie Prow; Angela Bosco-Lauth; Aaron C Brault; Richard A Bowen; Roy A Hall; Alexander A Khromykh
Journal:  J Virol       Date:  2012-12-12       Impact factor: 5.103

3.  Plasticity of a critical antigenic determinant in the West Nile virus NY99 envelope protein domain III.

Authors:  Jessica A Plante; Maricela Torres; Claire Y-H Huang; David W C Beasley
Journal:  Virology       Date:  2016-06-07       Impact factor: 3.616

4.  An in vitro recombination-based reverse genetic system for rapid mutagenesis of structural genes of the Japanese encephalitis virus.

Authors:  Ruikun Du; Manli Wang; Zhihong Hu; Hualin Wang; Fei Deng
Journal:  Virol Sin       Date:  2015-09-30       Impact factor: 4.327

5.  Novel Synthesis and Phenotypic Analysis of Mutant Clouds for Hepatitis E Virus Genotype 1.

Authors:  Shubhra Agarwal; Prasith Baccam; Rakesh Aggarwal; Naga Suresh Veerapu
Journal:  J Virol       Date:  2018-01-30       Impact factor: 5.103

6.  Mechanism and significance of cell type-dependent neutralization of flaviviruses.

Authors:  Swati Mukherjee; Kimberly A Dowd; Carolyn J Manhart; Julie E Ledgerwood; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson
Journal:  J Virol       Date:  2014-04-16       Impact factor: 5.103

7.  Enhancing dengue virus maturation using a stable furin over-expressing cell line.

Authors:  Swati Mukherjee; Devika Sirohi; Kimberly A Dowd; Zhenguo Chen; Michael S Diamond; Richard J Kuhn; Theodore C Pierson
Journal:  Virology       Date:  2016-07-13       Impact factor: 3.616

8.  Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus.

Authors:  Pankaj Pal; Kimberly A Dowd; James D Brien; Melissa A Edeling; Sergey Gorlatov; Syd Johnson; Iris Lee; Wataru Akahata; Gary J Nabel; Mareike K S Richter; Jolanda M Smit; Daved H Fremont; Theodore C Pierson; Mark T Heise; Michael S Diamond
Journal:  PLoS Pathog       Date:  2013-04-18       Impact factor: 6.823

9.  Levels of Circulating NS1 Impact West Nile Virus Spread to the Brain.

Authors:  Alex W Wessel; Kimberly A Dowd; Scott B Biering; Ping Zhang; Melissa A Edeling; Christopher A Nelson; Kristen E Funk; Christina R DeMaso; Robyn S Klein; Janet L Smith; Thu Minh Cao; Richard J Kuhn; Daved H Fremont; Eva Harris; Theodore C Pierson; Michael S Diamond
Journal:  J Virol       Date:  2021-08-04       Impact factor: 6.549

10.  The type-specific neutralizing antibody response elicited by a dengue vaccine candidate is focused on two amino acids of the envelope protein.

Authors:  Laura A VanBlargan; Swati Mukherjee; Kimberly A Dowd; Anna P Durbin; Stephen S Whitehead; Theodore C Pierson
Journal:  PLoS Pathog       Date:  2013-12-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.